Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Drops By 5.3%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 17,610,000 shares, a drop of 5.3% from the September 30th total of 18,600,000 shares. Based on an average daily volume of 648,300 shares, the days-to-cover ratio is presently 27.2 days.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on KPTI shares. StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $5.00.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after purchasing an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $494,000. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $167,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $143,000. Finally, Exchange Traded Concepts LLC raised its holdings in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares in the last quarter. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Trading Down 8.7 %

Shares of Karyopharm Therapeutics stock opened at $0.90 on Friday. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $1.95. The stock’s fifty day simple moving average is $0.80 and its 200 day simple moving average is $0.92. The company has a market capitalization of $112.61 million, a PE ratio of -0.83 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. Analysts predict that Karyopharm Therapeutics will post -0.95 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).